As a researcher and professor of orthopaedic surgery, biochemistry, and molecular pharmacology at NYU School of Medicine, Philip Band is an expert in osteoarthritis, extracellular matrix, hyaluronic acid, synovial fluid, and intra-articular injection therapies. His work has spanned related fields, including medical applications of matrix polymers, orthopaedic medicine, injection devices, and recombinant botulinum neurotoxins. He was involved in founding the Center for Clinical Research created by Dr. Joseph Zuckerman, where he began developing big data approaches to personalized musculoskeletal medicine. Additionally, he serves as the chief executive officer of CytoDel LLC, a biopharmaceutical company that co-developed solutions with NYU Langone. His research includes engineering recombinant derivatives of botulinum neurotoxin to create therapeutic fusion proteins designed to deliver single chain antibodies to neurons. Throughout his career, he has been deeply involved in taking inventions from the laboratory to practical medical applications using preclinical testing, formulation, and chemistry manufacturing.